Cadrenal Therapeutics, Inc.

CVKD Nasdaq SEC CIK 1937993
Follow Cadrenal Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.2M +53.6% vs same quarter last year
EPS, diluted −$0.31 +76.3% vs same quarter last year
Operating cash flow −$1.9M +18.7% vs same quarter last year
Operating income −$1.3M +53.7% vs same quarter last year
Net income by quarter
−$4.2M
−$3.8M
−$3.7M
−$2.7M
−$3M
−$2.5M
−$3.3M
−$1.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$15M−$10M−$5M$0FY08FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$13.2M
FY24−$10.7M
FY23−$8.4M
FY22-
FY08-
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY08FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$12.6M
FY24−$7.4M
FY23−$3.5M
FY22-
FY08-